Company Analysis
Sign in

Dianthus Therapeutics, Inc. (DNTH)

Nasdaq: DNTH · Pharmaceutical Preparations · New York, NY · filing with the SEC since 2016
Full chart Alerts Compare
Grade4.2
◀ Past 3.0● Present 5.8▶ Future 3.5
2 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

16 patents granted to the 5 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Dianthus Therapeutics, Inc.’s names, not what it holds today.

Patents granted
16
16 utility, 1976 to Dec 31, 2025
Granted in 2025
1
Against 1 in 2024 and 1 in 2023
Applications published
67
2 of them in 2025
Names they are printed under
5
a former name, a subsidiary, its own name
By yearGrantedApplications published
'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals7
Biotechnology1
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name5 counted
Magenta Therapeutics, Inc. a former name
named as the applicant on its applications, in US
0 granted
59 published
Magenta Therapeutics, Inc. a former name
US, as the owner printed on each patent
14 granted
4 published
DIANTHUS THERAPEUTICS OPCO, INC. a subsidiary
named as the applicant on its applications, in US
0 granted
3 published
DIANTHUS THERAPEUTICS OPCO, INC. a subsidiary
US, as the owner printed on each patent
2 granted
0 published
DIANTHUS THERAPEUTICS, INC. its own name
named as the applicant on its applications, in US
0 granted
1 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Mar 18, 202512,252,550Antibodies that bind to C1S and uses thereofBiotechnologyDIANTHUS THERAPEUTICS OPCO, INC.
Oct 8, 202412,110,344Antibodies that bind to cis and uses thereofPharmaceuticalsDIANTHUS THERAPEUTICS OPCO, INC.
Feb 7, 202311,572,411Anti-CD117 antibodies and conjugatesPharmaceuticalsMagenta Therapeutics, Inc.
Mar 1, 202211,260,079Dosing regimens for the mobilization of hematopoietic stem and progenitor cellsPharmaceuticalsMagenta Therapeutics, Inc.
Jan 25, 202211,229,711Linkers for antibody-drug conjugates and related compounds, compositions, and methods of usePharmaceuticalsMagenta Therapeutics, Inc.
Feb 16, 202110,919,900Aryl hydrocarbon receptor antagonists and uses thereofPharmaceuticalsMagenta Therapeutics, Inc.
Jan 26, 202110,899,843Compositions and methods for the depletion of CD117+ cellsPharmaceuticalsMagenta Therapeutics, Inc.
Jan 5, 202110,882,915Compositions and methods for the depletion of CD117+ cellsPharmaceuticalsMagenta Therapeutics, Inc.
Sep 22, 202010,781,259Modified antibodies and related compounds, compositions, and methods of usePharmaceuticalsMagenta Therapeutics, Inc.
Apr 21, 202010,624,973Methods for the depletion of cellsPharmaceuticalsMagenta Therapeutics, Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Jun 26, 20252025/0206814PHARMACEUTICAL COMPOSITIONS COMPRISING ANTIBODIES FOR TREATMENT OF C1S MEDIATED DISORDERS AND METHODS OF USING THE SAMEPharmaceuticalsDIANTHUS THERAPEUTICS OPCO, INC.
Jun 12, 20252025/0188188ANTIBODIES THAT BIND TO C1S AND USES THEREOFPharmaceuticalsDIANTHUS THERAPEUTICS OPCO, INC.
Jun 27, 20242024/0207428COMPOSITIONS AND METHODS FOR THE DEPLETION OF CELLSPharmaceuticalsMagenta Therapeutics, Inc.
May 23, 20242024/0166769ANTIBODIES THAT BIND TO C1S AND USES THEREOFPharmaceuticalsDIANTHUS THERAPEUTICS OPCO, INC. · patent 12,110,344 granted from it
Mar 7, 20242024/0075157FC SILENCED ANTIBODY DRUG CONJUGATES (ADCS) AND USES THEREOFBiotechnologyMagenta Therapeutics, Inc.
Dec 28, 20232023/0414565COMPOSITIONS AND METHODS FOR TREATING HEMATOLOGICAL MALIGNANCIESPharmaceuticalsMagenta Therapeutics, Inc.
Dec 7, 20232023/0390412COMPOSITIONS AND METHODS FOR ALLOGENEIC TRANSPLANTATIONPharmaceuticalsMagenta Therapeutics, Inc.
Oct 19, 20232023/0330185METHODS AND COMPOSITIONS FOR TRANSDUCING HEMATOPOIETIC STEM AND PROGENITOR CELLS IN VIVOPharmaceuticalsMagenta Therapeutics, Inc.
Jun 15, 20232023/0183344T-CELL BISPECIFIC BINDING PROTEINSBiotechnologyMagenta Therapeutics, Inc.
Apr 27, 20232023/0130646DOSING REGIMENS FOR THE MOBILIZATION OF HEMATOPOIETIC STEM CELLSPharmaceuticalsMagenta Therapeutics, Inc.
What it applied for, 2024 to 2025: Pharmaceuticals 4 · Biotechnology 1.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton DNTH · research, not advice